These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 27487323)

  • 1. Community Pharmacists' Perspectives on Dispensing Medications With the Potential for Misuse, Diversion, and Intentional Overdose: Results of a Province-Wide Survey of Community Pharmacists in Canada.
    Leong C; Alessi-Severini S; Sareen J; Enns MW; Bolton J
    Subst Use Misuse; 2016 Nov; 51(13):1724-30. PubMed ID: 27487323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacists' role in opioid overdose: Kentucky pharmacists' willingness to participate in naloxone dispensing.
    Freeman PR; Goodin A; Troske S; Strahl A; Fallin A; Green TC
    J Am Pharm Assoc (2003); 2017; 57(2S):S28-S33. PubMed ID: 28139459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention.
    Eukel HN; Skoy E; Werremeyer A; Burck S; Strand M
    J Contin Educ Health Prof; 2019; 39(1):7-12. PubMed ID: 30614959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of community pharmacy-based services for type-2 diabetes in an Indonesian setting: pharmacist survey.
    Wibowo Y; Parsons R; Sunderland B; Hughes J
    Int J Clin Pharm; 2015 Oct; 37(5):873-82. PubMed ID: 25986291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacists' role in addressing opioid abuse, addiction, and diversion.
    J Am Pharm Assoc (2003); 2014; 54(1):e5-15. PubMed ID: 24257743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
    Haggerty LC; Gatewood SS; Goode JKR
    J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Student pharmacists' attitudes, perceptions, and knowledge regarding opioid use, misuse, and overdose: Four years of data.
    Murnane KS; Augustine JM; Marshall LL
    Curr Pharm Teach Learn; 2022 Oct; 14(10):1222-1228. PubMed ID: 36283793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulating gabapentin as a drug of abuse: A survey study of Kentucky community pharmacists.
    Blackmer J; Lindahl E; Strahl A; Schadler A; Freeman PR
    J Am Pharm Assoc (2003); 2019; 59(3):379-382. PubMed ID: 30786971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of pharmacy practice on community pharmacists' integration of medication and lab value information from electronic health records.
    Hughes CA; Guirguis LM; Wong T; Ng K; Ing L; Fisher K
    J Am Pharm Assoc (2003); 2011; 51(5):591-8. PubMed ID: 21896456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal.
    Nielsen S; Menon N; Larney S; Farrell M; Degenhardt L
    Addiction; 2016 Dec; 111(12):2177-2186. PubMed ID: 27367125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
    Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
    J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reviewing state-mandated training requirements for naloxone-dispensing pharmacists.
    Roberts AW; Carpenter DM; Smith A; Look KA
    Res Social Adm Pharm; 2019 Feb; 15(2):222-225. PubMed ID: 29650444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the RESPOND Toolkit on community pharmacists' opioid safety attitudes, self-efficacy, and knowledge.
    Irwin AN; Novak K; Alley L; Havlin T; O'Kane N; Johnston K; Hildebran C; Carson J; Hartung DM
    J Am Pharm Assoc (2003); 2020; 60(3):450-455.e3. PubMed ID: 31919007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moving opioid misuse prevention upstream: A pilot study of community pharmacists screening for opioid misuse risk.
    Strand MA; Eukel H; Burck S
    Res Social Adm Pharm; 2019 Aug; 15(8):1032-1036. PubMed ID: 30031696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applying the capability, opportunity, motivation, and behavior model to identify opportunities to increase pharmacist comfort dispensing naloxone in Texas: A structural equation modeling approach.
    Varisco TJ; Downs CG; Rathburn KR; Fleming ML; Thornton JD
    Int J Drug Policy; 2020 Sep; 83():102827. PubMed ID: 32589581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community pharmacists' experiences and people at risk of suicide in Canada and Australia: a thematic analysis.
    Murphy AL; Ataya R; Himmelman D; O'Reilly C; Rosen A; Salvador-Carulla L; Martin-Misener R; Burge F; Kutcher S; Gardner DM
    Soc Psychiatry Psychiatr Epidemiol; 2018 Nov; 53(11):1173-1184. PubMed ID: 29936597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What is known about community pharmacy supply of naloxone? A scoping review.
    Nielsen S; Van Hout MC
    Int J Drug Policy; 2016 Jun; 32():24-33. PubMed ID: 26949189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication.
    Hagemeier NE; Murawski MM; Lopez NC; Alamian A; Pack RP
    Res Social Adm Pharm; 2014; 10(3):562-75. PubMed ID: 23981913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.